TuHURA Biosciences Inc Cash Flow Conversion Efficiency
TuHURA Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has a cash flow conversion efficiency ratio of -0.467x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.63 Million) by net assets ($18.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TuHURA Biosciences Inc (2014–2026)
Cash flow conversion efficiency of TuHURA Biosciences Inc from 2014 to 2026. This chart illustrates how TuHURA Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HURA stock price and chart for real-time trading data and today's change.
TuHURA Biosciences Inc Cash Flow Conversion Ratio Explained
TuHURA Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TuHURA Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TuHURA Biosciences Inc ranked by their cash flow conversion efficiency. Also see HURA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lippo General Insurance Tbk
JK:LPGI
|
0.125x |
|
Lavras Gold Corp
V:LGC
|
-0.018x |
|
GBM Resources Ltd
AU:GBZ
|
-0.012x |
|
Maywood Acquisition Corp. 2 Class A Ordinary Share
NASDAQ:MYX
|
-1.341x |
|
Nien Hsing Textile Co Ltd
TW:1451
|
-0.022x |
|
Daishin Securities Co Ltd Pref 2
KO:003547
|
-0.385x |
|
John Hancock Investors Closed Fund
NYSE:JHI
|
0.038x |
|
Qilian International Holding Group Limited
NASDAQ:BGM
|
0.006x |
Annual Cash Flow Conversion Efficiency for TuHURA Biosciences Inc (2014–2026)
The table below shows the annual cash flow conversion efficiency of TuHURA Biosciences Inc from 2014 to 2026. Review TuHURA Biosciences Inc (HURA) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $20.93 Million | $-27.63 Million | -1.320x | -30.79% |
| 2025-06-30 | $14.59 Million | $-14.73 Million | -1.009x | -113.16% |
| 2024-06-30 | $-1.56 Million | $-11.95 Million | 7.667x | +1356.40% |
| 2023-06-30 | $12.30 Million | $-7.51 Million | -0.610x | -106.95% |
| 2022-06-30 | $-747.82K | $-6.56 Million | 8.777x | +592.39% |
| 2021-06-30 | $10.58 Million | $-18.86 Million | -1.782x | +94.09% |
| 2020-06-30 | $263.00K | $-7.93 Million | -30.144x | -837.35% |
| 2019-06-30 | $1.97 Million | $-6.33 Million | -3.216x | -77.44% |
| 2018-06-30 | $5.44 Million | $-9.85 Million | -1.812x | -48.68% |
| 2017-06-30 | $6.58 Million | $-8.02 Million | -1.219x | -15.10% |
| 2016-06-30 | $4.86 Million | $-5.15 Million | -1.059x | -122.58% |
| 2015-06-30 | $-821.49K | $-3.85 Million | 4.690x | -30.50% |
| 2014-06-30 | $-817.98K | $-5.52 Million | 6.749x | -- |
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more